Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Peter Leung
Sandoz Ltd.’s lawsuit to clear the way for its generic version of the Prezista HIV drug will now go to the Court of Justice of the European Union.
The England and Wales Court of Appeal (Civil) Jan. 25 referred the dispute to the EU’s top court, to clarify how to determine whether a particular product is covered by a supplementary protection certificate (SPC), which extends the protection term for certain patent rights for drugs. SPCs are governed by EU law and are designed to make up for some of the patent protection term lost to the market approval process.
The CJEU’s decision will provide guidance on how to analyze whether an SPC actually covers the drug it is supposed to protect. Generic drug companies often attack the SPC as a way to clear the way for their own versions of the drug.
Johnson & Johnson, the parent of the patent owner Janssen Sciences Ireland UC, reported in 2017 $1.82 billion in worldwide sales of drugs with darunavir, the generic name for Prezista.
Sandoz sued Janssen arguing that the SPC for Prezista actually doesn’t cover the product. Janssen’s SPC is based on its patent covering Prezista, but the analysis for whether a product is covered by an SPC is different from the test to determine if a product is covered by a patent.
The trial court sided with Janssen, saying that the SPC covered Prezista.
On appeal, Sandoz didn’t dispute that the drug is covered by the patent, but argued that EU law requires that SPCs describe the protected chemical more specifically. The SPC covering Prezista, which expires in February 2019, doesn’t meet that higher threshold, Sandoz said.
One complexity stems from how the patent was drafted. The patent claim didn’t specifically describe the structure of darunavir, but instead covered all variations of a disclosed chemical structure in a type of claim known as a Markush formula. According to Sandoz’s expert witness the patent claim covers trillions of possible chemical compounds.
The Court of Appeal said that under its own interpretation of EU law, the SPC would protect Prezista, but there were several unanswered questions that must be referred to the CJEU before it could issue a definitive ruling.
The Court of Appeal said the test it favored would look at whether product covered by the SPC “embodies the core inventive advance of the basic patent.” Darunavir would be protected by the SPC under that approach, because a skilled person would immediately recognize that the patent claim describes darunavir, the active ingredient and the core of the invention, the court said.
However, it isn’t clear that approach is the correct one, the court said. Some CJEU cases require that the product protected by the SPC be “specified” or “identified.” In those cases, the Prezista SPC wouldn’t cover darunavir because the patent on which it is based doesn’t specifically disclose the active ingredient of the drug, the court said.
Lord Justice Christopher Floyd wrote the opinion, which Lord Justices Kim Lewison and David Kitchin joined. Fieldfisher LLP represented Sandoz, and Charlotte May and William Duncan were the barristers. Bristows LLP represented Janssen, and Thomas Mitcheson and Stuart Baran were the barristers.
The case is Sandoz Ltd. v. GD Searle LLC ,  EWCA Civ 49, EWCA (Civ) (U.K.), No. A3 2017 1483, 1/25/18 .
To contact the reporter on this story: Peter Leung in Washington at email@example.com
To contact the editor responsible for this story: Mike Wilczek at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)